ASCO 2024: Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD1 therapy in patients with metastatic melanoma
ASCO 2024: Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD1 therapy in patients with metastatic melanoma
Despite the advances made by the introduction of immune-checkpoint inhibitor therapy there is still an unmet medical need for patients with metastatic melanoma. Personalized vaccines, targeting mutation-derived neoantigens (neoAgs), represent a promising frontier in cancer immunotherapy that can further boost the induction of tumor specific T-cells. In this study, we identified and selected tumor-specific neoAgs using the proprietary vaccine target discovery AI-ImmunologyTM platform based on tumor DNA- and RNA-sequencing data. The top-ranked neoAgs (max. 10 neoAgs) for each patient were manufactured as synthetic long peptides and formulated with an liposomal adjuvant, creating the personalized cancer vaccine, EVX-01, tailored to the individual tumor and immune system characteristics. Here we report on vaccine- induced immune responses in 12 metastatic melanoma patients treated with the AI-designed personalized cancer vaccine, EVX-01, in the ongoing single arm multicenter Phase 2 trial (NCT05309421).
